Cardiac Amyloidosis: from Heart Failure to Multiple Myeloma, a Case Report

1 Dubrey S, Hawkins P, Falk R. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011; 97(1): 75–84. DubreyS HawkinsP FalkR Amyloid diseases of the heart: assessment, diagnosis, and referral Heart 2011 97 1 75 84 10.1136/hrt.2009.19040521148582 Search in Google Scholar

2 Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, Massie R, Narayan J, Swiggum E, Venner CP. Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis. Can J Cardiol 2020; 36(3): 322–34. FineNM DavisMK AndersonK DelgadoDH GiraldeauG KitchluA MassieR NarayanJ SwiggumE VennerCP Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis Can J Cardiol 2020 36 3 322 34 10.1016/j.cjca.2019.12.03432145862 Search in Google Scholar

3 Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005; 95(4): 535–7. MurtaghB HammillSC GertzMA KyleRA TajikAJ GroganM Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement Am J Cardiol 2005 95 4 535 7 10.1016/j.amjcard.2004.10.02815695149 Search in Google Scholar

4 Stana A, Matei C, Ginghină C. Factori de prognostic clinici şi paraclinici în amiloidoza cardiacă - Studiu retrospectiv. Romanian Journal of Cardiology 2011; 21(4): 322–4. StanaA MateiC GinghinăC Factori de prognostic clinici şi paraclinici în amiloidoza cardiacă - Studiu retrospectiv Romanian Journal of Cardiology 2011 21 4 322 4 Search in Google Scholar

5 Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, Marwick TH, Thomas JD. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012; 98(19): 1442–8. PhelanD CollierP ThavendiranathanP PopovićZB HannaM PlanaJC MarwickTH ThomasJD Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis Heart 2012 98 19 1442 8 10.1136/heartjnl-2012-30235322865865 Search in Google Scholar

6 Baccouche H, Maunz M, Beck T, Gaa E, Banzhaf M, Knayer U, Fogarassy P, Beyer M. Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography. Echocardiography 2012; 29(6): 668–77. BaccoucheH MaunzM BeckT GaaE BanzhafM KnayerU FogarassyP BeyerM Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography Echocardiography 2012 29 6 668 77 10.1111/j.1540-8175.2012.01680.x22486396 Search in Google Scholar

7 Stricagnoli M, Cameli M, Incampo E, Lunghetti S, Mondillo S. Speckle tracking echocardiography in cardiac amyloidosis. Heart Fail Rev 2019; 24(5): 701–7. StricagnoliM CameliM IncampoE LunghettiS MondilloS Speckle tracking echocardiography in cardiac amyloidosis Heart Fail Rev 2019 24 5 701 7 10.1007/s10741-019-09796-z30989593 Search in Google Scholar

8 Kristen AV, Perz JB, Schonland SO, Hansen A, Hegenbart U, Sack F-U, Goldschmidt H, Katus HA, Dengler TJ. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant 2007; 26(12): 1313–9. KristenAV PerzJB SchonlandSO HansenA HegenbartU SackF-U GoldschmidtH KatusHA DenglerTJ Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis J Heart Lung Transplant 2007 26 12 1313 9 10.1016/j.healun.2007.09.01418096484 Search in Google Scholar

9 Minnema MC, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma PF, Kröger N, Wu KL, Kersten MJ, Schaafsma MR. Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica 2019; 104(11): 2274. MinnemaMC NasserinejadK HazenbergB HegenbartU VlummensP YpmaPF KrögerN WuKL KerstenMJ SchaafsmaMR Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial Haematologica 2019 104 11 2274 10.3324/haematol.2018.213900682161030923094 Search in Google Scholar

10 Barrett CD, Alexander KM, Zhao H, Haddad F, Cheng P, Liao R, Wheeler MT, Liedtke M, Schrier S, Arai S. Outcomes in patients with cardiac amyloidosis undergoing heart transplantation. JACC Heart Fail 2020; 8(6): 461–8. BarrettCD AlexanderKM ZhaoH HaddadF ChengP LiaoR WheelerMT LiedtkeM SchrierS AraiS Outcomes in patients with cardiac amyloidosis undergoing heart transplantation JACC Heart Fail 2020 8 6 461 8 10.1016/j.jchf.2019.12.01332387068 Search in Google Scholar

11 Release FN. FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis. 2019. https://www.fda.gov/ (accessed 28.01.2021). ReleaseFN FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis 2019 https://www.fda.gov/ (accessed 28.01.2021). Search in Google Scholar

12 Release PP. European comissioon approves Vyndaqel®, the first treatment in the EU for transthyretin amyloid cardiomyopathy (ATTR-CM). 2020. https://www.pfizer.com/news/ (accessed 28.01. 2021). ReleasePP European comissioon approves Vyndaqel®, the first treatment in the EU for transthyretin amyloid cardiomyopathy (ATTR-CM) 2020 https://www.pfizer.com/news/ (accessed 28.01. 2021). Search in Google Scholar

13 Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379(11): 1007–16. MaurerMS SchwartzJH GundapaneniB ElliottPM MerliniG Waddington-CruzM KristenAV GroganM WittelesR DamyT Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy N Engl J Med 2018 379 11 1007 16 10.1056/NEJMoa180568930145929 Search in Google Scholar

14 release FN. FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis. 2021. https://www.fda.gov/ (accessed 28.01.2021). release FN FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis 2021 https://www.fda.gov/ (accessed 28.01.2021). Search in Google Scholar

15 Sanchorawala V, Sarosiek S, Schulman A, Mistark M, Migre ME, Cruz R, Sloan JM, Brauneis D, Shelton AC. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood 2020; 135(18): 1541–7. SanchorawalaV SarosiekS SchulmanA MistarkM MigreME CruzR SloanJM BrauneisD SheltonAC Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study Blood 2020 135 18 1541 7 10.1182/blood.2019004436719318531978210 Search in Google Scholar

16 Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood 2020; 136(1): 71–80. PalladiniG KastritisE MaurerMS ZonderJ MinnemaMC WechalekarAD JaccardA LeeHC BummaN KaufmanJL Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA Blood 2020 136 1 71 80 10.1182/blood.2019004460733289732244252 Search in Google Scholar

17 Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, Syed II, Hughes DA, Lust JA, Jaffe AS. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007; 116(21): 2420–6. FengD EdwardsWD OhJK ChandrasekaranK GroganM MartinezMW SyedII HughesDA LustJA JaffeAS Intracardiac thrombosis and embolism in patients with cardiac amyloidosis Circulation 2007 116 21 2420 6 10.1161/CIRCULATIONAHA.107.69776317984380 Search in Google Scholar

18 Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol 2020; 6(4): 351–61. GiancaterinoS UreyMA DardenD HsuJC Management of arrhythmias in cardiac amyloidosis JACC Clin Electrophysiol 2020 6 4 351 61 10.1016/j.jacep.2020.01.00432327068 Search in Google Scholar

19 El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, Noseworthy PA, Lin G, Pislaru SV, Egbe AC. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. Am J Cardiol 2019; 73(5): 589–97. El-AmEA DispenzieriA MelduniRM AmmashNM WhiteRD HodgeDO NoseworthyPA LinG PislaruSV EgbeAC Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis Am J Cardiol 2019 73 5 589 97 10.1016/j.jacc.2018.10.079637868530732713 Search in Google Scholar

20 Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC, Garcia-Pavia P, Gillmore JD, Hawkins PN, Fontana M. High prevalence of intracardiac thrombi in cardiac amyloidosis. Am J Cardiol 2019; 73(13): 1733–4. Martinez-NaharroA Gonzalez-LopezE CorovicA MirelisJG BaksiAJ MoonJC Garcia-PaviaP GillmoreJD HawkinsPN FontanaM High prevalence of intracardiac thrombi in cardiac amyloidosis Am J Cardiol 2019 73 13 1733 4 10.1016/j.jacc.2019.01.03530947929 Search in Google Scholar

21 Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK. Arrhythmias in cardiac amyloidosis: challenges in risk stratification and treatment. Can J Cardiol 2020; 36(3): 416–23. CheungCC RostonTM AndradeJG BennettMT DavisMK Arrhythmias in cardiac amyloidosis: challenges in risk stratification and treatment Can J Cardiol 2020 36 3 416 23 10.1016/j.cjca.2019.11.03932145868 Search in Google Scholar

22 Mitrani LR, De Los Santos J, Helmke S, Biviano AB, Maurer MS. Anticoagulation with warfarin versus novel oral anticoagulants in atrial fibrillation in amyloid transthyretin amyloidosis cardiomyopathy: a retrospective cohort study. J Card Fail 2019; 25(8): S82. MitraniLR De Los SantosJ HelmkeS BivianoAB MaurerMS Anticoagulation with warfarin versus novel oral anticoagulants in atrial fibrillation in amyloid transthyretin amyloidosis cardiomyopathy: a retrospective cohort study J Card Fail 2019 25 8 S82 10.1016/j.cardfail.2019.07.233 Search in Google Scholar

23 Mohanty S, TRIVEDI CG, Gallinghouse J, Della Rocca DG, Gianni C, MacDonald B, Mayedo A, Bassiouny M, Gallinghouse G, Burkhardt J. Best Anticoagulation Strategy for Stroke Prophylaxis in Atrial Fibrillation Patients With Amyloidosis. Circulation 2020; 142(Suppl_3): A15073-A. MohantyS TRIVEDICG GallinghouseJ Della RoccaDG GianniC MacDonaldB MayedoA BassiounyM GallinghouseG BurkhardtJ Best Anticoagulation Strategy for Stroke Prophylaxis in Atrial Fibrillation Patients With Amyloidosis Circulation 2020 142 Suppl_3 A15073-A 10.1161/circ.142.suppl_3.15073 Search in Google Scholar

24 Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112(13): 2047–60. FalkRH Diagnosis and management of the cardiac amyloidoses Circulation 2005 112 13 2047 60 10.1161/CIRCULATIONAHA.104.48918716186440 Search in Google Scholar

25 Dispenzieri A, Gertz M, Kyle R, Lacy M, Burritt M, Therneau T, Greipp P, Witzig T, Lust J, Rajkumar S, Fonseca R, Zeldenrust S, McGregor C, Jaffe A. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 15(22): 3751–7. DispenzieriA GertzM KyleR LacyM BurrittM TherneauT GreippP WitzigT LustJ RajkumarS FonsecaR ZeldenrustS McGregorC JaffeA Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis J Clin Oncol 2004 15 22 3751 7 10.1201/9781420037494-24 Search in Google Scholar

26 Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30(9): 989. KumarS DispenzieriA LacyMQ HaymanSR BuadiFK ColbyC LaumannK ZeldenrustSR LeungN DingliD Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements J Clin Oncol 2012 30 9 989 10.1200/JCO.2011.38.5724367568022331953 Search in Google Scholar

27 Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood 2019; 133(3): 215–23. LillenessB RubergFL MussinelliR DorosG SanchorawalaV Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis Blood 2019 133 3 215 23 10.1182/blood-2018-06-85895130333122 Search in Google Scholar

28 Pun SC, Landau HJ, Riedel ER, Jordan J, Anthony FY, Hassoun H, Chen CL, Steingart RM, Liu JE. Prognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantation. J Am Soc Echocardiogr 2018; 31(1): 64–70. PunSC LandauHJ RiedelER JordanJ AnthonyFY HassounH ChenCL SteingartRM LiuJE Prognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantation J Am Soc Echocardiogr 2018 31 1 64 70 10.1016/j.echo.2017.08.017598566429111123 Search in Google Scholar

29 Adam R, Jercan A, Badelita S, Coriu D, Stan C, Serban M, Beladan C, Rosca M, Balahura A, Ginghina C. P216 Cardiac amyloidosis is not a single disease: an echocardiographic study of light chain vs transthyretin forms. Eur Heart J Cardiovasc Imaging 2020; 21(Supplement_1): jez319. 083. AdamR JercanA BadelitaS CoriuD StanC SerbanM BeladanC RoscaM BalahuraA GinghinaC P216 Cardiac amyloidosis is not a single disease: an echocardiographic study of light chain vs transthyretin forms Eur Heart J Cardiovasc Imaging 2020 21 Supplement_1 jez319. 083 10.1093/ehjci/jez319.083 Search in Google Scholar

30 Suhr OB, Anan I, Backman C, Karlsson A, Lindqvist P, Mörner S, Waldenström A. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008; 263(3): 294–301. SuhrOB AnanI BackmanC KarlssonA LindqvistP MörnerS WaldenströmA Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008 263 3 294 301 10.1111/j.1365-2796.2007.01888.x18069997 Search in Google Scholar

31 Kristen AV, Maurer MS, Rapezzi C, Mundayat R, Suhr OB, Damy T, investigators T. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis–Report from the Transthyretin Amyloidosis Outcome Survey (THAOS). PLoS One 2017; 12(4): e0173086. KristenAV MaurerMS RapezziC MundayatR SuhrOB DamyT investigators T Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis–Report from the Transthyretin Amyloidosis Outcome Survey (THAOS) PLoS One 2017 12 4 e0173086 10.1371/journal.pone.0173086538303028384285 Search in Google Scholar